<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="07/02/22" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=8913871" creator="Yumiko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>8913871</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Potent <term sem="Other" id="T1" lex="gene_regulatory_activity"><term sem="DNA_molecule" id="A2">gene</term> regulatory</term> and <term sem="Other" id="T2" lex="antiproliferative_activity">antiproliferative activities</term> of <term sem="Organic_compound_other" id="A1"><term sem="Organic_compound_other" id="T3" lex="20-methyl_analogue">20-methyl analogues</term> of <term sem="Lipid" id="T4" lex="1,25_dihydroxyvitamin_D3">1,25 dihydroxyvitamin D3</term></term>.</sentence>
<event id="E1">
<type class="Regulation" />
<theme idref="A2" />
<cause idref="A1" />
<clue>Potent gene <clueType>regulatory</clueType> and antiproliferative activities <linkCause>of</linkCause> 20-methyl analogues of 1,25 dihydroxyvitamin D3.</clue>
<comment>TPS A1</comment>
</event>
<event id="E2">
<type class="Negative_regulation" />
<cause idref="A1" />
<clue>Potent gene regulatory and <clueType>antiproliferative activities</clueType> <linkCause>of</linkCause> 20-methyl analogues of 1,25 dihydroxyvitamin D3.</clue>
<comment>NO THEME</comment>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The biological active form of <term sem="Lipid" id="T5" lex="vitamin_D3">vitamin D3</term>, <term sem="Lipid" id="T6" lex="1,25-dihydroxyvitamin_D3">1,25-dihydroxyvitamin D3</term> (<term sem="Lipid" id="T7" lex="VD">VD</term>), regulates <term sem="Other" id="A3"><term sem="Other" id="A10">cellular</term> growth</term> and <term sem="Other" id="A11">differentiation</term>.</sentence>
<event id="E4">
<type class="Positive_regulation" />
<theme idref="T7" />
<clue>The biological <clueType>active form</clueType> <linkTheme>of</linkTheme> vitamin D3, 1,25-dihydroxyvitamin D3 (VD), regulates cellular growth and differentiation.</clue>
</event>
<event id="E3">
<type class="Regulation" />
<theme idref1="A11" idref="A10" />
<cause idref="E4" />
<clue>The biological active form of vitamin D3, 1,25-dihydroxyvitamin D3 (VD), <clueType>regulates</clueType> cellular growth and differentiation.</clue>
</event>
<event id="E6">
<type class="Regulation" />
<theme idref="A3" />
<cause idref="E4" />
<clue>The biological active form of vitamin D3, 1,25-dihydroxyvitamin D3 (VD), <clueType>regulates</clueType> cellular growth and differentiation.</clue>
</event>
<sentence id="S3">This provides the <term sem="Protein_molecule" id="A4">hormone with an interesting therapeutic potential</term>.</sentence>
<event id="E7">
<type class="Positive_regulation" />
<theme idref="A4" />
<cause idref="T7" />
<clue><corefCause>This</corefCause> <clueType>provides</clueType> the hormone with an interesting therapeutic potential.</clue>
<comment>TPS A4</comment>
</event>
<sentence id="S4">However, <term sem="Other" id="T9" lex="hypercalcemia">hypercalcemia</term> is a side effect, which is caused by <term sem="Lipid" id="T10" lex="VD">VD</term>&apos;s classical action, the regulation of <term sem="Other" id="T11" lex="calcium_homeostasis"><term sem="Element" id="T12" lex="calcium">calcium</term> homeostasis</term>.</sentence>
<event id="E80">
<type class="Physiological_process" />
<theme idref="T12" />
<clue>However, hypercalcemia is a side effect, which is caused by VD&apos;s classical action, the regulation of calcium <clueType>homeostasis</clueType>.</clue>
</event>
<event id="E8">
<type class="Regulation" />
<theme idref="E80" />
<cause idref="T10" />
<clue>However, hypercalcemia is a side effect, which is caused by VD&apos;s classical action, the <clueType>regulation</clueType> <linkTheme>of</linkTheme> calcium homeostasis.</clue>
</event>
<event id="E9">
<type class="Positive_regulation" />
<theme idref="T9" />
<cause idref="E8" />
<clue>However, hypercalcemia is a side effect, which is <clueType>caused</clueType> <linkCause>by</linkCause> <corefCause>VD&apos;s classical action</corefCause>, the regulation of calcium homeostasis.</clue>
</event>
<sentence id="S5">This made the need for <term sem="Organic_compound_other" id="A5"><term sem="Lipid" id="T13" lex="VD">VD</term> analogues</term> with selectively increased <term sem="Other" id="T14" lex="cell_regulatory_property">cell regulatory properties</term>.</sentence>
<event id="E10">
<type class="Regulation" />
<cause idref="A5" />
<clue>This made the need for VD analogues with selectively increased <clueType>cell regulatory properties</clueType>.</clue>
<comment>NO THEME</comment>
</event>
<event id="E11">
<type class="Positive_regulation" />
<theme idref="E10" />
<clue>This made the need for VD analogues with selectively <clueType>increased</clueType> cell regulatory properties.</clue>
</event>
<sentence id="S6">Studies with <term sem="Organic_compound_other" id="T15" lex="20-epi_analogue">20-epi analogues</term> pointed out the importance of the carbon-20 position and led to the development of <term sem="Organic_compound_other" id="T16" lex="20-methyl_derivative">20-methyl derivatives</term> of <term sem="Lipid" id="T17" lex="VD">VD</term>.</sentence>
<sentence id="S7">In this report the biological properties of the compounds <term sem="Organic_compound_other" id="T18" lex="ZK161422">ZK161422</term> and <term sem="Organic_compound_other" id="T19" lex="ZK157202">ZK157202</term>, which are <cons sem="(AND Organic_compound_other Organic_compound_other)" id="T20" lex="(AND 20-methyl-eneanalogue 20-methyl-23-eneanalogue)"><frag id="F1">20-methyl-</frag> and <frag id="F2">20-methyl-23-</frag><frag id="F3">eneanalogues</frag></cons>, respectively, have been analyzed in comparison with <term sem="Lipid" id="T21" lex="VD">VD</term>.</sentence>
<sentence id="S8">Both compounds show about 2-fold lower affinity to the <term sem="Lipid" id="T22" lex="VD">VD</term> receptor (<term sem="Protein_family_or_group" id="A6">VDR</term>) than <term sem="Lipid" id="T23" lex="VD">VD</term>.</sentence>
<event id="E12">
<type class="Binding" />
<theme idref="T18" />
<theme idref="A6" />
<clue><corefTheme idref1="T18">Both compounds</corefTheme> show about 2-fold <clueType>lower affinity</clueType> <linkTheme>to</linkTheme> the VD receptor (VDR) than VD.</clue>
</event>
<event id="E13">
<type class="Binding" />
<theme idref="T19" />
<theme idref="A6" />
<clue><corefTheme idref1="T19">Both compounds</corefTheme> show about 2-fold <clueType>lower affinity</clueType> <linkTheme>to</linkTheme> the VD receptor (VDR) than VD.</clue>
</event>
<event id="E14">
<type class="Binding" />
<theme idref="T18" />
<theme idref="T23" />
<clue><corefTheme idref1="T18">Both compounds</corefTheme> show about 2-fold lower <clueType>affinity</clueType> <linkTheme>to</linkTheme> the VD receptor (VDR) than VD.</clue>
</event>
<event id="E15">
<type class="Binding" />
<theme idref="T19" />
<theme idref="T23" />
<clue><corefTheme idref1="T19">Both compounds</corefTheme> show about 2-fold lower <clueType>affinity</clueType> <linkTheme>to</linkTheme> the VD receptor (VDR) than VD.</clue>
</event>
<sentence id="S9">However, compared to <term sem="Lipid" id="T24" lex="VD">VD</term>, their antiproliferative effect is up to 30-fold higher on <term sem="Cell_natural" id="T25" lex="human_peripheral_blood_mononuclear_cell">human peripheral blood mononuclear cells</term> and even up to 300-fold higher on <term sem="Cell_cultured" id="T26" lex="human_breast_cancer_MCF-7_cell">human breast cancer MCF-7 cells</term>.</sentence>
<event id="E16">
<type class="Cellular_physiological_process" />
<theme idref="T25" />
<clue>However, compared to VD, their <clueType>antiproliferative</clueType> effect is up to 30-fold higher on human peripheral blood mononuclear cells and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E17">
<type class="Cellular_physiological_process" />
<theme idref="T26" />
<clue>However, compared to VD, their <clueType>antiproliferative</clueType> effect is up to 30-fold higher on human peripheral blood mononuclear cells and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E18">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="T18" />
<clue>However, compared to VD, <corefCause>their</corefCause> <clueType>antiproliferative effect</clueType> is up to 30-fold higher <linkTheme>on</linkTheme> human peripheral blood mononuclear cells and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E19">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="T19" />
<clue>However, compared to VD, <corefCause>their</corefCause> <clueType>antiproliferative effect</clueType> is up to 30-fold higher <linkTheme>on</linkTheme> human peripheral blood mononuclear cells and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E20">
<type class="Negative_regulation" />
<theme idref="E17" />
<cause idref="T18" />
<clue>However, compared to VD, <corefCause>their</corefCause> <clueType>antiproliferative effect</clueType> is up to 30-fold higher on human peripheral blood mononuclear cells and even up to 300-fold higher <linkTheme>on</linkTheme> human breast cancer MCF-7 cells.</clue>
</event>
<event id="E21">
<type class="Negative_regulation" />
<theme idref="E17" />
<cause idref="T19" />
<clue>However, compared to VD, <corefCause>their</corefCause> <clueType>antiproliferative effect</clueType> is up to 30-fold higher on human peripheral blood mononuclear cells and even up to 300-fold higher <linkTheme>on</linkTheme> human breast cancer MCF-7 cells.</clue>
</event>
<event id="E22">
<type class="Positive_regulation" />
<theme idref="E19" />
<clue>However, compared to VD, their antiproliferative effect is <clueType>up to 30-fold higher</clueType> <clueLoc>on human peripheral blood mononuclear cells</clueLoc> and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E23">
<type class="Positive_regulation" />
<theme idref="E18" />
<clue>However, compared to VD, their antiproliferative effect is <clueType>up to 30-fold higher</clueType> <clueLoc>on human peripheral blood mononuclear cells</clueLoc> and even up to 300-fold higher on human breast cancer MCF-7 cells.</clue>
</event>
<event id="E24">
<type class="Positive_regulation" />
<theme idref="E20" />
<clue>However, compared to VD, their antiproliferative effect is <clueType>up</clueType> to 30-fold higher on human peripheral blood mononuclear cells and even up <clueType>to 300-fold higher</clueType> <clueLoc>on human breast cancer MCF-7 cells</clueLoc>.</clue>
</event>
<event id="E25">
<type class="Positive_regulation" />
<theme idref="E21" />
<clue>However, compared to VD, their antiproliferative effect is <clueType>up</clueType> to 30-fold higher on human peripheral blood mononuclear cells and even up <clueType>to 300-fold higher</clueType> <clueLoc>on human breast cancer MCF-7 cells</clueLoc>.</clue>
</event>
<sentence id="S10">Whereas the <term sem="Other" id="A8">hypercalcemic</term> effect for <term sem="Organic_compound_other" id="T27" lex="ZK157202">ZK157202</term> is also increased 10-fold, <term sem="Organic_compound_other" id="T28" lex="ZK161422">ZK161422</term> has the same <term sem="Other" id="T29" lex="calcium-mobilizing_potency"><term sem="Element" id="T30" lex="calcium">calcium</term>-mobilizing potency</term> as <term sem="Lipid" id="T31" lex="VD">VD</term>.</sentence>
<event id="E26">
<type class="Regulation" />
<theme idref="A8" />
<cause idref="T27" />
<clue>Whereas the hypercalcemic <clueType>effect</clueType> <linkCause>for</linkCause> ZK157202 is also increased 10-fold, ZK161422 has the same calcium-mobilizing potency as VD.</clue>
</event>
<event id="E27">
<type class="Positive_regulation" />
<theme idref="E26" />
<clue>Whereas the hypercalcemic effect for ZK157202 is also <clueType>increased</clueType> 10-fold, ZK161422 has the same calcium-mobilizing potency as VD.</clue>
</event>
<event id="E28">
<type class="Regulation" />
<theme idref="T30" />
<cause idref="T28" />
<clue>Whereas the hypercalcemic effect for ZK157202 is also increased 10-fold, ZK161422 has the same calcium-mobilizing <clueType>potency</clueType> as VD.</clue>
</event>
<sentence id="S11">Moreover, <term sem="Organic_compound_other" id="T32" lex="ZK161422">ZK161422</term>, but not <term sem="Organic_compound_other" id="T33" lex="ZK157202">ZK157202</term>, showed preference for gene activation from a <term sem="DNA_domain_or_region" id="A55"><term sem="DNA_domain_or_region" id="A12"><term sem="DNA_domain_or_region" id="T34" lex="promoter">promoter</term> carrying a <term sem="DNA_domain_or_region" id="T35" lex="VD_response_element"><term sem="Lipid" id="T36" lex="VD">VD</term> response element</term></term> with a <term sem="DNA_substructure" id="T37" lex="palindromic_arrangement">palindromic arrangement</term> of two <term sem="DNA_domain_or_region" id="T38" lex="hexameric_receptor_binding_site">hexameric receptor binding sites</term> spaced by <term sem="Polynucleotide" id="T39" lex="9_nucleotide">9 nucleotides</term> (<term sem="Polynucleotide" id="T40" lex="IP9">IP9</term>)</term> rather than for activation from a <term sem="DNA_domain_or_region" id="A14"><term sem="DNA_domain_or_region" id="T41" lex="response_element">response element</term> formed by a direct repeat spaced by <term sem="Polynucleotide" id="T42" lex="3_nucleotide">3 nucleotides</term></term> (<term sem="Polynucleotide" id="T43" lex="DR3">DR3</term>).</sentence>
<event id="E29">
<type class="Positive_regulation" />
<theme idref="A55" />
<clue>Moreover, ZK161422, but not ZK157202, showed preference for gene <clueType>activation</clueType> <linkTheme>from</linkTheme> a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than for activation from a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
<comment>TPS A55</comment>
</event>
<event id="E30">
<type class="Positive_regulation" />
<theme idref="A14" />
<clue>Moreover, ZK161422, but not ZK157202, showed preference for gene activation from a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than for <clueType>activation</clueType> <linkTheme>from</linkTheme> a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
<comment>TPS A14</comment>
</event>
<event id="E31">
<type class="Correlation" />
<theme idref="T32" />
<theme idref="E29" />
<clue>Moreover, ZK161422, but not ZK157202, showed <clueType>preference</clueType> <linkTheme>for</linkTheme> gene activation from a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than for activation from a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
</event>
<event id="E32">
<type class="Correlation" />
<theme idref="T32" />
<theme idref="E30" />
<clue>Moreover, ZK161422, but not ZK157202, showed <clueType>preference</clueType> for gene activation from a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than <linkTheme>for</linkTheme> activation from a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
</event>
<event assertion="non-exist" id="E33">
<type class="Correlation" />
<theme idref="T33" />
<theme idref="E29" />
<clue>Moreover, ZK161422, but not ZK157202, showed <clueType>preference</clueType> <linkTheme>for</linkTheme> gene activation from a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than for activation from a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
</event>
<event assertion="non-exist" id="E34">
<type class="Correlation" />
<theme idref="T33" />
<theme idref="E30" />
<clue>Moreover, ZK161422, but not ZK157202, showed <clueType>preference</clueType> <linkTheme>for</linkTheme> gene activation from a promoter carrying a VD response element with a palindromic arrangement of two hexameric receptor binding sites spaced by 9 nucleotides (IP9) rather than for activation from a response element formed by a direct repeat spaced by 3 nucleotides (DR3).</clue>
</event>
<sentence id="S12">This observation supports a model, in which <term sem="Other" id="T44" lex="promoter_selectivity">promoter selectivity</term> reflects the selectively increased <term sem="Other" id="T45" lex="antiproliferative_effect">antiproliferative effect</term> of <term sem="Organic_compound_other" id="T46" lex="VD_analogue"><term sem="Lipid" id="T47" lex="VD">VD</term> analogues</term>.</sentence>
<event id="E35">
<type class="Negative_regulation" />
<cause idref="T46" />
<clue>This observation supports a model, in which promoter selectivity reflects the selectively increased <clueType>antiproliferative effect</clueType> <linkCause>of</linkCause> VD analogues.</clue>
<comment>NO THEME</comment>
</event>
<event id="E36">
<type class="Positive_regulation" />
<theme idref="E35" />
<cause idref="T44" />
<clue>This observation supports a model, in which promoter selectivity reflects the selectively <clueType>increased</clueType> antiproliferative effect of VD analogues.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
